(Q28371264)

English

EGFR VIII

genetic variant

VIII

In more languages

Statements

disruptive inframe deletion

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

human chromosome 7

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

55087058

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

55223523

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

positive therapeutic predictor for

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/773

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/971

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

determination method

CIViC evidence level D

CIViC 1-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1017

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1128

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1128

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4500

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

negative therapeutic predictor for

docetaxel trihydrate / Cetuximab combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

head and neck squamous cell carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/848

Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

HGVS nomenclature

NM_005228.3:c.89_881del

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

NP_005219.2:p.Val30_Arg297delinsGly

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

NC_000007.13:g.55209979_55221845del

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/312

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371264&oldid=2014799122"